206 related articles for article (PubMed ID: 21508352)
21. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I
Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
23. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
24. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
[TBL] [Abstract][Full Text] [Related]
26. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
[TBL] [Abstract][Full Text] [Related]
27. Fold up or perish: unfolded protein response and chemotherapy.
Strasser A; Puthalakath H
Cell Death Differ; 2008 Feb; 15(2):223-5. PubMed ID: 18049478
[No Abstract] [Full Text] [Related]
28. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
29. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
30. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
33. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Ocker M; Alajati A; Ganslmayer M; Zopf S; Lüders M; Neureiter D; Hahn EG; Schuppan D; Herold C
J Cancer Res Clin Oncol; 2005 Jun; 131(6):385-94. PubMed ID: 15754201
[TBL] [Abstract][Full Text] [Related]
34. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
Liu N; Huang H; Xu L; Hua X; Li X; Liu S; Yang C; Zhao C; Zhao C; Li S; Dou QP; Liu J
Toxicol Lett; 2014 Jan; 224(3):333-40. PubMed ID: 24291039
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
37. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
39. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
40. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]